Skip to content

Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms

Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01170195
Enrollment
120
Registered
2010-07-27
Start date
2010-09-30
Completion date
2011-09-30
Last updated
2010-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Symptoms, Vaginal Dryness

Keywords

Postmenopausal, licorice, vaginal complaints

Brief summary

The purpose of the proposed study is to test the effect of Licorice Root Extract- Licogen on postmenopausal symptoms in postmenopausal women. Specifically, the study will also test the effect of the licorice extract on vaginal dryness.

Detailed description

The estrogenic properties of glabridin, the major isoflavan in licorice root, were tested in view of the resemblance of its structure and lipophilicity to those of estradiol. The results indicate that glabridin is a phytoestrogen, binding to the human estrogen receptor and stimulating creatine kinase activity in rat uterus, epiphyseal cartilage, diaphyseal bone, aorta, and left ventricle of the heart. The stimulatory effects of 2.5-25 mg/animal glabridin were similar to those of 5 mg/animal estradiol. Chemical modification of glabridin showed that the position of the hydroxyl groups has a significant role in binding to the human estrogen receptor and in proliferation-inducing activity. Glabridin was found to be three to four times more active than 2\*-O-methylglabridin and 4\*-O-methylglabridin, and both derivatives were more active than 2\*,4\*- O-methylglabridin. The effect of increasing concentrations of glabridin on the growth of breast tumor cells was biphasic. Glabridin showed an estrogen receptor-dependent, growth-promoting effect at low concentrations (10 nM-10 mM) and estrogen receptor-independent antiproliferative activity at concentrations of \>15 mM. This is the first study to indicate that isoflavans have estrogen-like activities. Glabridin and its derivatives exhibited varying degrees of estrogen receptor agonism in different tests and demonstrated growth-inhibitory actions on breast cancer cells.

Interventions

DIETARY_SUPPLEMENTCalmera-Licorice Root Extract (Licogen)

100 mg per day

Sponsors

F&C Licorice Ltd
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Women between the ages 45-60, 2. Who are post-menopausal (proved by a laboratory test of FSH \> 30 International units), 3. Patients who report having post-menopausal symptoms, who report having, at least 5-7 hot flushes per day, as well as wakeful night episodes and nocturnal sweating (measured by Greenscale or Cooperman Index).

Exclusion criteria

1. Female patients who are outside the age boundaries of 45-60, 2. Have FSH \<30 3. Patients who presently have cancer of any kind, 4. Patients that are on any other treatment for relieving post-menopausal symptoms 5. Patients who have contraindication to Licorice.

Design outcomes

Primary

MeasureTime frameDescription
A beneficial effect of the licorice extract on postmenopausal symptoms (vasomotor symptoms, and nocturnal episodes) in symptomatic postmenopausal women20 weeksThis outcome will be measured by: a diary in which she should report daily. The reporting would be for 3 parameters: number of hot flushes per day, wakefull night episodes and nocturnal sweating measured by Greens Climateric Scale
A beneficial effect of the licorice extract on vaginal complaints in symptomatic postmenopausal women20 weeksthis objective will be measured by Pap Smear, Vaginal Ultra sound and vaginal PH

Countries

Israel

Contacts

Primary ContactBoris Kaplan, MD
bkaplan@clalit.org.il972-3-9377534

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026